Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Overview
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Companies Involved in Therapeutics Development
AbbVie Inc
Abcuro Inc
Albireo Pharma Inc
Alexion Pharmaceuticals Inc
Ascletis Pharma Inc
Avolynt Inc
Calliditas Therapeutics AB
CAMP4 Therapeutics Corp
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Cour Pharmaceuticals Development Co Inc
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Escient Pharmaceuticals Inc
Future Medicine Co Ltd
Genfit SA
GenKyoTex SA
GentiBio Inc
Gilead Sciences Inc
Hanmi Pharmaceuticals Co Ltd
HighTide Therapeutics Inc
Kissei Pharmaceutical Co Ltd
Kowa Co Ltd
MediGene AG
Mirum Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Parvus Therapeutics Inc
PRISM Pharma Co Ltd
Selecta Biosciences Inc
Shaanxi Micot Technology Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Umecrine Cognition AB
Zydus Lifesciences Ltd
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drug Profiles
A-3907 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABC-008 - Drug Profile
Product Description
Mechanism Of Action
aldafermin - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASC-42 - Drug Profile
Product Description
Mechanism Of Action
AVO-1681 - Drug Profile
Product Description
Mechanism Of Action
bezafibrate SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
budesonide DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
bulevirtide - Drug Profile
Product Description
Mechanism Of Action
CNP-104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
elafibranor - Drug Profile
Product Description
Mechanism Of Action
History of Events
EP-547 - Drug Profile
Product Description
Mechanism Of Action
History of Events
golexanolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HTD-1801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MT-2004 - Drug Profile
Product Description
Mechanism Of Action
norursodeoxycholic acid - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotides for Primary Biliary Cholangitis - Drug Profile
Product Description
Mechanism Of Action
pemafibrate - Drug Profile
Product Description
Mechanism Of Action
PRI-724 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Primary biliary cholangitis - Drug Profile
Product Description
Mechanism Of Action
Primary Biliary Cholangitis (PBC) - Drug Profile
Product Description
Mechanism Of Action
History of Events
PVT-201 - Drug Profile
Product Description
Mechanism Of Action
remogliflozin etabote - Drug Profile
Product Description
Mechanism Of Action
History of Events
RhuDex - Drug Profile
Product Description
Mechanism Of Action
History of Events
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
History of Events
seladelpar lysine - Drug Profile
Product Description
Mechanism Of Action
History of Events
setaxib - Drug Profile
Product Description
Mechanism Of Action
History of Events
tiomolibdate choline - Drug Profile
Product Description
Mechanism Of Action
History of Events
TQA-3526 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ursodiol - Drug Profile
Product Description
Mechanism Of Action
History of Events
volixibat potassium - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZG-5266 - Drug Profile
Product Description
Mechanism Of Action
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Product Development Milestones
Featured News & Press Releases
Feb 15, 2022: First patient randomized in pivotal TRANSFORM study with setaxib
Feb 01, 2022: Liver Institute Northwest participating in RESPONSE, a global phase 3 clinical research study evaluating an investigatiol therapy for the treatment of Primary Biliary Cholangitis (PBC)
Dec 10, 2021: Zydus announces EPICS-III phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC
Nov 15, 2021: Gannex announces Chi NMPA approved phase II and III protocols of ASC42, an FXR agonist, for treatment of primary biliary cholangitis
Nov 15, 2021: CymaBay Therapeutics long-term open label study finds treatment with seladelpar for two years improves key liver biomarkers in patients with PBC
Nov 11, 2021: CymaBay Therapeutics to host post-AASLD key opinion leader webir on seladelpar for primary biliary cholangitis
Nov 02, 2021: New clinical data on GENFIT’s investigatiol compound Elafibranor to be presented at AASLD The Liver Meeting
Nov 02, 2021: Pincle Clinical Research, PLLC participating in RESPONSE, a global phase 3 clinical research study evaluating an investigatiol therapy for the treatment of Primary Biliary Cholangitis (PBC)
Oct 01, 2021: CymaBay Therapeutics announces presentations at The Liver Meeting 2021
Sep 06, 2021: Gannex announces clinical trial application of ASC42, an FXR agonist, for treatment of primary biliary cholangitis accepted by Chi NMPA
Aug 09, 2021: Calliditas receives FDA Fast Track Desigtion for setaxib in PBC
Jul 21, 2021: European Medicines Agency grants Orphan Drug Desigtion to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC)
Jun 24, 2021: Korea-US innovative bio-drug confirms the possibility of treating various rare liver diseases
Jun 23, 2021: Mirum Pharmaceuticals presents alyses from volixibat at the EASL Intertiol Liver Congress 2021
Jun 21, 2021: CymaBay Therapeutics presents positive PBC data at the Intertiol Liver Congress 2021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by AbbVie Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Abcuro Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Albireo Pharma Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Alexion Pharmaceuticals Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Ascletis Pharma Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Avolynt Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Calliditas Therapeutics AB, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by CAMP4 Therapeutics Corp, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Cour Pharmaceuticals Development Co Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by CymaBay Therapeutics Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Dr. Falk Pharma GmbH, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Escient Pharmaceuticals Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Future Medicine Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Genfit SA, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GenKyoTex SA, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GentiBio Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Gilead Sciences Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by HighTide Therapeutics Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Kowa Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by MediGene AG, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Mirum Pharmaceuticals Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by NGM Biopharmaceuticals Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Parvus Therapeutics Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by PRISM Pharma Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Selecta Biosciences Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Shaanxi Micot Technology Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Umecrine Cognition AB, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Zydus Lifesciences Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects, 2022 (Contd..1)
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products, 2022